Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site

Daniel Stadlbauer, Meagan McMahon, Hannah L. Turner, Xueyong Zhu, Hongquan Wan, Juan Manuel Carreño, George O’Dell, Shirin Strohmeier, Zain Khalil, Marta Luksza, Harm van Bakel, Viviana Simon, Ali H. Ellebedy, Ian A. Wilson, Andrew B. Ward, Florian Krammer

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Contemporary influenza A H3N2 viruses circulating since 2016 have acquired a glycosylation site in the neuraminidase in close proximity to the enzymatic active site. Here, we investigate if this S245N glycosylation site, as a result of antigenic evolution, can impact binding and function of human monoclonal antibodies that target the conserved active site. While we find that a reduction in the inhibitory ability of neuraminidase active site binders is measurable, this class of broadly reactive monoclonal antibodies maintains protective efficacy in vivo.

Original languageEnglish
Article number7864
JournalNature communications
Volume13
Issue number1
DOIs
StatePublished - Dec 2022

Fingerprint

Dive into the research topics of 'Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site'. Together they form a unique fingerprint.

Cite this